使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen. Welcome to Henry Schein's fourth-quarter 2025 earnings conference call.
各位女士、先生,早安。歡迎參加 Henry Schein 2025 年第四季財報電話會議。
(Operator Instructions)
(接線員指示)
As a reminder, this call is being recorded.
提醒各位,本次電話會議將被錄音。
I would now like to introduce you to your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.
現在我想向各位介紹今天會議的主持人:Henry Schein 投資人關係副總裁暨策略性財務專案主管 Graham Stanley。Graham,請開始。
Graham Stanley - Vice President, Investor Relations and Strategic Financial Project Officer
Graham Stanley - Vice President, Investor Relations and Strategic Financial Project Officer
Thank you, operator, and thanks to each of you for joining us today to discuss Henry Schein's financial results for the fourth quarter of 2025.
謝謝接線員,也感謝各位今天加入我們,一同討論 Henry Schein 2025 年第四季的財務結果。
With me on today's call is Stanley Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein; Fred Lowery, Chief Executive Officer Designate of Henry Schein; and Ron South, Senior Vice President and Chief Financial Officer.
今天與我一同參與電話會議的有:Henry Schein 董事會主席兼執行長 Stanley Bergman;Henry Schein 候任執行長 Fred Lowery;以及資深副總裁兼財務長 Ron South。
Before we begin, I'd like to state that certain comments made during this call will include information that's forward-looking. Risks and uncertainties involved in the company's business may affect the matters referred to in forward-looking statements, and the company's performance may materially differ from those expressed in or indicated by such statements.
在開始之前,我想先聲明,本次電話會議中的部分評論將包含前瞻性資訊。公司業務所涉及的風險與不確定性可能影響前瞻性陳述中所提及的事項,且公司的實際表現可能與該等陳述所表達或暗示者存在重大差異。
These forward-looking statements are qualified in their entirety by the cautionary statements contained in Henry Schein's filings with the Securities and Exchange Commission and included in the risk factors section of those filings. In addition, all comments about the markets we serve, including end market growth rates and market share, are based upon the company's internal analyses and estimates.
這些前瞻性陳述在其整體上均受 Henry Schein 向美國證券交易委員會提交之文件中的警示性聲明所限制,並包含於該等文件的風險因素章節中。此外,所有關於我們所服務市場的評論(包括終端市場成長率與市占率)均係基於公司內部分析與估計。
Today's remarks will include both GAAP and non-GAAP financial results. We believe the non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.
今天的發言將同時包含 GAAP 與非 GAAP 的財務結果。我們相信,非 GAAP 財務衡量指標可為投資人提供有用的補充資訊,以了解我們業務的財務表現,並可在某些項目可能獨立於業務表現而變動的情況下,協助比較各期間的財務結果,同時也能就管理層用於營運業務的關鍵指標提供更高透明度。
These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures.
這些非 GAAP 財務衡量指標僅供資訊與比較之用,不應被視為相對應 GAAP 指標的替代。
Reconciliations between GAAP and non-GAAP measures are included in exhibit B of today's press release and can be found in the financials and filing section of our investor relations website under the supplemental information heading, and in our quarterly earnings presentation also posted on our Investor Relations website.
GAAP 與非 GAAP 指標之間的調節表載於今日新聞稿的附件 B,亦可於我們投資人關係網站的「財務與申報」專區中「補充資訊」項下查閱,並可在同樣發布於投資人關係網站的季度財報簡報中找到。
The content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, February 24, 2026. Henry Schein undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.
本次電話會議內容包含具時效性的資訊,僅在直播當日(2026 年 2 月 24 日)為準確。Henry Schein 不承擔在本次電話會議日期之後,因事件或情況變化而修訂或更新任何前瞻性陳述的義務。
Lastly, during today's Q&A session, please limit yourself to a single question so that we can accommodate questions from as many as you as possible.
最後,在今天的問答環節中,請各位每人僅提一個問題,以便我們能盡可能回覆更多人的提問。
And with that, I'd like to turn the call over to Stanley Bergman.
接下來,我想把電話會議交給 Stanley Bergman。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Graham. Good morning, everyone, and thank you for joining us.
謝謝你,Graham。各位早安,感謝各位加入我們。
I want to particularly welcome Fred Lowery to our call today. Fred will officially join Henry Schein next week as our new CEO. I will continue to serve as the Chairman of the Board. We're very pleased Fred will be leading the company and believe he's exceptionally well suited for the role. He is joining us from Thermo Fisher Scientific where he spent 20 years scaling large businesses to acquisitions and organic growth, managing both national and owned brand products sold through Thermo Fisher's distribution channels and advancing value-added services.
我特別要歡迎 Fred Lowery 今天加入我們的電話會議。Fred 將於下週正式加入 Henry Schein,擔任我們的新任執行長。我將繼續擔任董事會主席。我們非常高興由 Fred 帶領公司,並相信他非常適合這個職務。他來自 Thermo Fisher Scientific,在那裡任職 20 年,透過併購與有機成長擴大大型事業規模,管理透過 Thermo Fisher 配銷通路銷售的全國性品牌與自有品牌產品,並推進加值服務。
Fred also brings a strong customer focus. Beyond Fred's extensive leadership experience, Fred has a philosophy that aligns with the principles that have long defined Henry Schein. He understands the critical role we have in supporting dental and medical practitioners, and he is very well equipped to lead Henry Schein into its next phase of growth. Fred has already connected with many of our leaders, leadership -- with many in our leadership team and I'm highly confident that the transition to Fred's leadership will be smooth and that he will drive Henry Schein to even greater success.
Fred 也具備強烈的客戶導向。除了 Fred 豐富的領導經驗之外,他的理念也與長期以來界定 Henry Schein 的原則一致。他了解我們在支持牙科與醫療從業人員方面所扮演的關鍵角色,並且具備充分能力帶領 Henry Schein 進入下一階段的成長。Fred 已經與我們許多領導者建立連結,領導層——也與我們領導團隊中的許多人交流;我非常有信心,過渡到 Fred 的領導將會順利,他也將推動 Henry Schein 取得更大的成功。
Fred, could you please make a few remarks? Thank you.
Fred,你能否發表幾點談話?謝謝。
Fred Lowery - Chief Executive Officer Designate
Fred Lowery - Chief Executive Officer Designate
Thank you, Stan. I'm excited to be here today and I'm looking forward to getting started next week and working with this high-performance team and leading this exceptional company into its next phase of growth. I also look forward to engaging with our five constituents; our Team Schein members, our customers, suppliers. Investors, and the communities which we serve.
謝謝你,Stan。我很高興今天能在這裡,也期待下週開始投入工作,與這支高績效團隊共事,並帶領這家卓越的公司邁入下一階段的成長。我也期待與我們的五大利害關係人互動:我們的 Team Schein 成員、客戶、供應商、投資人,以及我們所服務的社區。
I have an enormous amount of respect for what Stan and Team Schein have built, and I'm committed to building upon these achievements going forward.
我非常敬重 Stan 與 Team Schein 所建立的一切,並承諾未來將在這些成就之上持續發展。
As I've gotten to know the Henry Schein Team and the company over the past couple of months, I've been impressed with the values, the culture, and the significant growth opportunities for the future. The fourth-quarter results demonstrate that I'm joining a company that is successfully managing through transformation, which is exactly the kind of experience I've led effectively in prior roles.
在過去幾個月逐步認識 Henry Schein 團隊與公司之後,我對其價值觀、文化,以及未來顯著的成長機會印象深刻。第四季的結果顯示,我加入的是一家正成功管理轉型的公司,而這正是我在先前職務中曾有效帶領的經驗類型。
So to you, Stan, thank you and to the entire leadership team, thank you for warmly welcoming me over the past few months. It's yet another indication of the company's unique culture. Henry Schein is a great company, and I look forward to leading the team as we accelerate the implementation of our strategies.
因此,Stan,謝謝你;也謝謝整個領導團隊在過去幾個月對我的熱情歡迎。這也再次展現了公司獨特的文化。Henry Schein 是一家很棒的公司,我期待帶領團隊加速推動我們策略的落實。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Fred, for your thoughtful comments, which, in my mind, reiterates why we have great confidence that you will lead Henry Schein to even greater success.
謝謝你,Fred,你深思熟慮的評論在我看來再次印證了我們為何對你能帶領 Henry Schein 取得更大成功充滿信心。
Now to the fourth-quarter results.
現在談第四季的結果。
Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particularly our global equipment, specialty products, and technology businesses. This drove our strong fourth-quarter earnings, which exceeded the increased 2025 financial guidance we provided in our third-quarter earnings release. The growth we have achieved, especially over the second half of 2025, demonstrates the effective execution of our 2025 to 2027 BOLD+1 strategic plan and positions us well for the future.
我們第四季的銷售反映出持續的動能,帶來 15 個季度以來最高的銷售成長。我們對各項業務的銷售表現感到滿意,尤其是我們的全球設備、專業產品與科技業務。這帶動了我們強勁的第四季獲利,並超越了我們在第三季財報新聞稿中所提供、且已上調的 2025 年財務指引。我們所達成的成長,特別是在 2025 年下半年,展現了我們對 2025 至 2027 年 BOLD+1 策略計畫的有效執行,並使我們在未來具備良好定位。
Let me highlight some of the initiatives that have advanced our BOLD+1 strategic plan in this particular quarter.
我想重點說明本季推進我們 BOLD+1 策略計畫的一些措施。
First, 2025 non-GAAP operating income from high-growth, high-margin businesses is approaching 50% of our total operating income. We are on track to exceed our goal of over 50% by the end of our strategic planning cycle in 2027. This does not include income from our corporate brands, which we estimate to be more than 10% of our total operating income.
第一,2025 年來自高成長、高毛利業務的非 GAAP 營業利益正接近我們總營業利益的 50%。我們正朝著在 2027 年策略規劃週期結束前超過 50% 目標的方向前進。此數字不包含我們企業品牌的收益;我們估計企業品牌收益占我們總營業利益的比重超過 10%。
Second, implementation is underway across multiple value creation projects, and we are pleased with the progress made to date.
第二,多項價值創造專案已在推動落實中,我們對目前取得的進展感到滿意。
Third, we have made substantial progress rolling out our global e-commerce platform, now known as henryschein.com, and expect to complete the rollout to the US dental and Canadian customers in the first quarter of this year and to US medical customers shortly thereafter. We will then continue with global implementation of henryschein.com.
第三,我們在推動全球電子商務平台(現稱為 henryschein.com)的上線方面已取得重大進展,並預期將於今年第一季完成對美國牙科與加拿大客戶的上線,並在其後不久完成對美國醫療客戶的上線。之後我們將持續推進 henryschein.com 的全球導入。
We have also launched a number of innovative solutions that provide our customers with the tools to enhance patient care and to operate a more efficient practice, including exclusive distribution in the US and the UK of Vvardis' Curodont product, a unique solution for detection and treatment of early-stage caries, and we also have now a very strong partnership with Amazon Web Services for both generative and agentic AI integration with Henry Schein One. These are both key achievements and indicative of the marketplace's view of Henry Schein, our ability to help practitioners, and of course, drive in the end shareholder value.
我們也推出多項創新解決方案,為客戶提供工具以提升病患照護並更有效率地經營診所,其中包括在美國與英國獨家經銷 Vvardis 的 Curodont 產品(這是一項用於早期齲齒偵測與治療的獨特解決方案);此外,我們目前也與 Amazon Web Services 建立非常強大的合作夥伴關係,將生成式與代理式 AI 整合至 Henry Schein One。這兩項都是關鍵成果,並反映市場對 Henry Schein 的看法、我們協助執業者的能力,當然最終也能推動股東價值。
We recently completed a survey, this is very important, of the US dental market to assess customers' financial and operational needs and opportunities for us to add value in this arena. The survey indicated that practices focus includes driving revenue growth and improving operational efficiency by adding new customers and reducing appointment cancellations, rescheduling, or delayed treatments. These findings reinforce our confidence in our strategies, which are contained in the BOLD+1 strategy to support our customers, elevating clinical care, and of course improve patient outcome, generating higher practice performance, and integrating efficient proprietary workflows.
我們最近完成了一項調查——這非常重要——針對美國牙科市場,以評估客戶的財務與營運需求,以及我們在此領域可創造價值的機會。調查顯示,診所的重點在於推動營收成長並提升營運效率,方式包括增加新客戶,以及降低約診取消、改期或延後治療的情況。這些發現強化了我們對策略的信心;這些策略已納入 BOLD+1 策略之中,用以支持客戶、提升臨床照護,並改善病患治療結果,進而帶來更高的診所績效,並整合高效率的專有工作流程。
So this survey is very clear. Of course, patient outcomes are critical to our customers, but generating high-practice performance and integrating efficient propriety workflows that we offer are also critical to the future of the practice as viewed by dentists and as I said, contained in our BOLD+1 strategic plan. We believe that customers recognize the value we bring and that these benefits are reflected in our sales results as we continue with the momentum on the sales side.
因此,這份調查非常清楚。當然,病患治療結果對我們的客戶至關重要,但如牙醫所認為的,產生高診所績效並整合我們所提供的高效率專有工作流程,同樣對診所的未來至關重要;正如我所說,這些都包含在我們的 BOLD+1 策略計畫中。我們相信客戶認可我們帶來的價值,而這些效益也反映在我們的銷售成果上,因為我們在銷售端持續保持動能。
So turning now to review of our businesses. Let me start with the global distribution and value-added services group where we delivered solid fourth-quarter sales results and good growth driven by continued momentum from the prior few quarters.
接下來回顧我們的業務。我先從全球分銷與加值服務事業群談起;我們在第四季交出穩健的銷售成果,並在前幾季延續的動能帶動下實現良好成長。
We estimate approximately halfof the US and medical distribution merchandise sales growth was driven by higher volume. Data derived from our Henry Schein One e-claims activity also indicates signs of modest procedure growth in the US. We believe that in general, patient traffic remains stable and probably leaning positively in the quarter. And I think that is really the direction of where dentistry is heading in the US for the short-term, maybe medium-term.
我們估計,美國牙科與醫療分銷商品銷售成長約有一半是由更高的銷量所帶動。從 Henry Schein One 的電子理賠(e-claims)活動所衍生的數據也顯示,美國的處置量出現溫和成長的跡象。我們認為整體而言,病患就診量仍維持穩定,且本季可能略偏正向。我認為這確實是美國牙科在短期、也許中期的發展方向。
US dental merchandise sales growth reflected continued market share gains versus last year. Our January US dental merchandise sales this January reflected the good momentum going into the first quarter of '26, and we continue to see benefits from increased sales performance throughout data-driven marketing programs. We've invested heavily in this data-driven marketing arena for the last couple of years, and I think of course this is gaining momentum, but I think you will gain even further momentum as Henry Schein One is adopted in the marketplace as the key digital ordering and engagement platform for those interested in dental merchandise.
美國牙科商品銷售成長反映出相較去年持續提升的市占率。我們今年一月的美國牙科商品銷售,反映出進入 2026 年第一季的良好動能;同時,我們也持續看到透過數據驅動行銷方案提升銷售績效所帶來的效益。過去幾年我們在數據驅動行銷領域投入甚鉅,我認為這當然正在累積動能;而且隨著 Henry Schein One 在市場上被採用為牙科商品的關鍵數位訂購與互動平台,動能還會進一步提升。
Our global dental equipment sales hit a record this quarter and sales growth was the highest since the post-COVID recovery of 2021. We believe we are gaining market share in equipment resulting from outstanding execution of our long-term strategy of investing in this area, both on the sales side with our suppliers of course in that connection but also on the equipment installation and server side through our global distribution network.
本季我們的全球牙科設備銷售創下新高,且銷售成長為 2021 年 COVID 後復甦以來最高。我們相信,透過在此領域長期策略的卓越執行——包括在銷售端與供應商的合作,當然也包括透過全球分銷網路在設備安裝與伺服端的投入——我們正在提升設備市占率。
On the equipment side, we believe that we provide our customers with the broadest product offering of equipment and the largest and best trained technical support capabilities in the industry on a global basis as well. US dental equipment sales were excellent, delivering double-digit growth. Traditional equipment sales drove much of this growth bolstered by some exclusive supplier sponsored promotions and we are pleased that we are able to provide above-market growth for those suppliers that are on our platform and work closely with us. We had good order intake, which continues by the way into the first quarter, as our customers remain confident in investing in their practices and investing in their practices through Henry Schein.
在設備方面,我們相信我們在全球範圍內為客戶提供業界最廣泛的設備產品組合,以及最大且訓練最完善的技術支援能力。美國牙科設備銷售表現優異,實現雙位數成長。傳統設備銷售帶動了大部分成長,並受惠於部分供應商贊助的獨家促銷活動;我們也很高興能為在我們平台上、並與我們密切合作的供應商提供高於市場的成長。我們的接單表現良好,而且順帶一提,這股趨勢延續到第一季,因為客戶仍對投資其診所充滿信心,並透過 Henry Schein 投資其診所。
Digital equipment sales increased in the low single-digits. We saw good unit growth across 2D, 3D imaging, mills, 3D printers, and intraoral scanners. Intraoral scanners average selling prices continue to modestly decrease due to lower prices of new market entrants, but I hasten to add that these new market entrants are also attracting new customers into the space advancing the interest in the practitioner community to advance from manual impressions to digital impressions. This movement continues, although I might also add that there's still lots of room for converting dentists from manual impressions to digital impressions.
數位設備銷售以低個位數成長。我們在 2D、3D 影像、研磨機、3D 印表機與口內掃描器等品類都看到良好的出貨量成長。由於新進入者以較低價格切入市場,口內掃描器的平均售價持續小幅下降;但我必須補充的是,這些新進入者也正在吸引新客戶進入此領域,推動執業者社群從手工印模轉向數位印模的興趣。這股趨勢仍在持續;不過我也要補充,將牙醫從手工印模轉換為數位印模仍有很大的成長空間。
Parts and technical service sales remained solid contributors with mid-single-digit sales growth during the quarter. We are encouraged by the underlying demand trends in the US dental equipment market and in particular as it relates to customers viewing us as the supplier, and we expect to growth in 2026.
零件與技術服務銷售仍是穩健的貢獻來源,本季銷售成長為中個位數。我們對美國牙科設備市場的基本需求趨勢感到鼓舞,特別是就客戶將我們視為供應商而言;我們預期 2026 年將持續成長。
Turning to our US medical business, sales growth reflected steady demand for medical products and pharmaceuticals, along with continued strong performance in the home solutions portion of our medical business. This was partially offset by lower comparative demand for respiratory products -- in the respiratory product category, which we see continuing into the first quarter. The demand for tests and general respiratory visits has gone down, but the rest of the business has great momentum.
談到我們的美國醫療業務,銷售成長反映出對醫療產品與藥品的穩定需求,以及我們醫療業務中居家解決方案(home solutions)部分持續強勁的表現。這部分被呼吸道產品的相對需求下降所部分抵銷——在呼吸道產品類別中,我們預期此趨勢將延續到第一季。檢測需求與一般呼吸道就診次數已下降,但其餘業務動能非常強。
During the fourth quarter, our US medical business signed and launched an exclusive agreement with CytoChip Inc. to distribute its flagship, CitoCBC. The flagship system, CitoCBC, is a unique cartridge-based complete blood count analyzer providing lab quality results in approximately 8 minutes. We expect the system to expand access to lab quality hematology testing at the point of care. While revenue from this product is not expected to be material to the overall medical distribution business, this agreement reflects our strategy of bringing innovative products to our costs in partnership with suppliers that value the effectiveness of our distribution system.
在第四季,我們的美國醫療業務與 CytoChip Inc. 簽署並啟動一項獨家協議,經銷其旗艦產品 CitoCBC。該旗艦系統 CitoCBC 是一款獨特的卡匣式全血球計數(CBC)分析儀,可在約 8 分鐘內提供具實驗室品質的結果。我們預期該系統將擴大在照護現場(point of care)取得實驗室品質血液學檢測的可近性。雖然此產品的營收預期不會對整體醫療分銷業務造成重大影響,但這項協議反映了我們的策略:與重視我們分銷系統效能的供應商合作,將創新產品帶給我們的客戶。
International general merchandise sales grew well in constant currencies and experienced solid growth across most markets. Overall sales growth benefited from a weaker US dollar. International dental equipment sales growth was the strongest in many years and also grew well in constant currencies. Growth was broad-based and across many countries and across equipment categories. So this was pretty broad based globally and in the general equipment categories, the major ones all doing quite well on an international basis. International equipment sales growth benefited from currency exchange rates too.
國際一般商品銷售以固定匯率計算成長良好,且在多數市場均呈現穩健成長。整體銷售成長受惠於美元走弱。國際牙科設備銷售成長為多年來最強,且以固定匯率計算同樣表現良好。成長動能廣泛分布於多個國家與多個設備品類。因此,這在全球範圍內相當廣泛,且在一般設備品類中,主要品類在國際市場的表現都相當不錯。國際設備銷售成長也受惠於匯率變動。
On the value-added services side, sales growth was driven by our international business and by acquisitions to some extent. Also the general consulting part of the business is doing well.
在加值服務方面,銷售成長主要由我們的國際業務所帶動,並在一定程度上受惠於併購。此外,業務中的一般顧問服務部分也表現良好。
Now to the Global Specialty Products group. Fourth-quarter sales continue to benefit from strong performance in implants and biomaterials, and we believe we continue to gain share across most markets. Growth was driven primarily by BioHorizons' Camlog in Germany, S.I.N. in Brazil, and Biotech Dental in France, which each delivered double-digit growth. Overall international implant sales reflect solid underlying patient demand, reliable brands, and excellent product support and education programs.
現在來看全球專科產品(Global Specialty Products)事業群。第四季銷售持續受惠於植體與生物材料的強勁表現,我們相信在多數市場持續提升市占。成長主要由 BioHorizons 的 Camlog(德國)、S.I.N.(巴西)以及 Biotech Dental(法國)所帶動,三者皆繳出雙位數成長。整體國際植體銷售反映出穩健的患者需求、可靠的品牌,以及優異的產品支援與教育訓練計畫。
In the US, BioHorizons Camlog implant and biomaterials also grew at a rate consistent with prior quarters. S.I.N. value implant, the system from our Brazilian subsidiary, was introduced into the US market in the fourth quarter, and we expect this implant system to contribute to US growth this year in 2026.
在美國,BioHorizons Camlog 植體與生物材料也以與前幾季一致的速度成長。S.I.N. 平價植體(由我們巴西子公司提供的系統)於第四季導入美國市場,我們預期該植體系統將在今年 2026 年為美國成長帶來貢獻。
Endodontics continues to benefit from expanded commercial reach. We're distributing more of the endodontic products through our US distribution team. Also to some of the distribution channels outside of the US, so that is helping advance our endodontics business. Orthodontics, of course, which remains a small part of our specialty products business, also started to recently sell through our US dental distribution channel and has stabilized. The orthopedic business also performed well. Overall, we remain encouraged by the sales results across our specialty portfolio.
根管治療(Endodontics)持續受惠於商業觸及範圍的擴大。我們透過美國的通路團隊分銷更多根管治療產品。也透過部分美國以外的分銷通路,因此有助於推進我們的根管治療業務。當然,矯正(Orthodontics)在我們的專科產品業務中仍占比不大,近期也開始透過我們的美國牙科分銷通路銷售,並已趨於穩定。骨科(Orthopedic)業務表現也很不錯。整體而言,我們對專科產品組合的銷售成果仍感到鼓舞。
Now, let's turn to the Global Technology sales performance and that group in general. The performance was driven by core practice management solutions. We also had growth in our revenue cycle management solutions resulting from enhanced functionality, including electronic claims and electronic billing. These were all quite good in the quarter.
接著我們來看全球科技(Global Technology)的銷售表現以及該事業群的整體情況。表現主要由核心診所管理解決方案所帶動。我們的營收循環管理(Revenue Cycle Management)解決方案也因功能強化而成長,包括電子理賠與電子帳單。這些在本季表現都相當不錯。
This quarter our cloud-based customers increased by more than 20% year on year over year, primarily from new accounts and now we have more than 11,000 Dentrix Ascend and Dentally subscribers, and of course, the largest installed base in the world. We have also aligned our subscription offerings to provide more comprehensive integrated solutions. The standard Dentrix Ascend subscription now covers basic practice management, revenue cycle management, imaging, and patient experience solutions.
本季我們的雲端客戶數年增超過 20%,主要來自新客戶;目前 Dentrix Ascend 與 Dentally 訂閱戶已超過 11,000 家,當然也是全球最大的裝機基礎。我們也已調整訂閱方案,使其能提供更全面的整合式解決方案。標準的 Dentrix Ascend 訂閱方案現在涵蓋基本診所管理、營收循環管理、影像,以及病患體驗解決方案。
As a result of both the expanding customer base and product integration, we are driving growth in annual recurring SaaS subscription revenue, as well as growing our transactional services business. This ecosystem is doing well for our smaller customers, our mid-size customers, and the very large DSOs, and in turn driving profitability, for the business, for the Henry Schein One business and therefore profitability for the company in general.
在客戶基礎擴大與產品整合的雙重帶動下,我們推動年度經常性 SaaS 訂閱營收成長,同時也擴大我們的交易型服務業務。這個生態系對我們的小型客戶、中型客戶以及非常大型的 DSO(牙科服務組織)都運作良好,進而帶動業務獲利能力、帶動 Henry Schein One 事業的獲利,並因此提升公司整體獲利。
We made meaningful progress on AI initiatives through our new partnership with Amazon Web Services, as I noted, integrating its generative AI technology into Dentrix Ascend, Dentrix, and Dentally. This includes our real-time documentation assistant; Voice Notes, which uses AI to capture and summarize patient interactions; as well as voice activated charting, scheduling, and communications tools. These are projects that have been worked on over the last year or so and actually are now functioning very well in our customers' offices.
如我先前提到的,透過與 Amazon Web Services 的新合作夥伴關係,我們在 AI 計畫上取得了實質進展,將其生成式 AI 技術整合至 Dentrix Ascend、Dentrix 與 Dentally。這包括我們的即時文件助理;Voice Notes(語音筆記),利用 AI 擷取並摘要病患互動內容;以及語音啟動的病歷圖表記錄、排程與溝通工具。這些專案在過去一年左右持續推進,現在實際上已在客戶診所中運作得非常良好。
In addition, we launched Image Verify at last week's Chicago Midwinter show. This is an AI powered quality assessment tool that evaluates clinical images at the moment of capture, thereby helping reduce claims denials. Claims denials, as those that are familiar with the dental professional, is a real issue in the dental practice. This alone will attract customers to our system.
此外,我們在上週的芝加哥 Midwinter 展會推出了 Image Verify。這是一款 AI 驅動的品質評估工具,可在影像拍攝當下評估臨床影像,從而協助降低理賠遭拒的情況。對熟悉牙科專業的人而言,理賠遭拒確實是牙科診所的一大問題。僅此一項就能吸引客戶使用我們的系統。
During the quarter, we launched a new Forms workflow that captured insurance information from a simple photograph of a patient's card, making patient's record entry faster and more accurate.
本季我們推出新的表單(Forms)工作流程,只需拍攝病患保險卡的簡單照片即可擷取保險資訊,使病患資料建檔更快速且更精準。
In addition, we continue to enhance Eligibility Pro through faster response times and standard payer connections. We expect these ongoing developments to help customers drive incremental revenue, increase productivity across their practice, and therefore allow the practitioner to focus on quality of care rather than administrative functions which our system is increasingly taking care of in a very, very user friendly way.
此外,我們持續透過更快的回應時間與標準化的付款方(payer)連線來強化 Eligibility Pro。我們預期這些持續的開發將協助客戶帶來增量營收、提升診所整體生產力,並讓醫師能專注於照護品質,而非行政作業;而我們的系統正以非常、非常友善的方式,愈來愈多地承擔這些工作。
With that, I will now turn the call over to Ron to review our fourth-quarter financial results and discuss our 2026 financial guidance.
接下來,我將把電話會議交給 Ron,請他回顧我們第四季的財務結果,並說明我們 2026 年的財務指引。
Thank you, everyone, for calling in and listening and Ron, now over to you.
謝謝各位來電收聽,Ron,接下來交給你。
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Thank you, Stanley. Good morning, everyone.
謝謝你,Stanley。各位早安。
Today I will review the financial highlights for the quarter and would like to remind investors that on our Investor Relations website, we have also included a financial presentation containing additional detailed financial information, including certain reportable segment information.
今天我將回顧本季的財務重點,並提醒投資人:在我們的投資人關係網站上,我們也提供了一份財務簡報,包含更多詳細的財務資訊,包括部分可報導分部(reportable segment)資訊。
Starting with our fourth-quarter sales results, global sales were $3.4 billion with sales growth of 7.7% compared with the fourth quarter of 2024, reflecting constant currency sales growth of 5.8% and a 1.9% increase resulting from foreign currency exchange. Acquisitions contributed 0.9% sales growth to the quarter.
先從第四季銷售結果開始,全球銷售額為 34 億美元,較 2024 年第四季成長 7.7%,其中反映固定匯率(constant currency)銷售成長 5.8%,以及因外匯匯率變動帶來的 1.9% 增加。併購為本季銷售成長貢獻 0.9%。
Our GAAP operating margin for the fourth quarter of 2025 was 4.76%, a decrease of 10 basis points compared to the prior year GAAP operating margin.
2025 年第四季 GAAP 營業利益率為 4.76%,較前一年 GAAP 營業利益率下降 10 個基點。
On a non-GAAP basis, the operating margin for the fourth quarter was 7.42%, relatively flat compared to the prior year, despite slightlylower gross margins, primarily a result of product mix within the Global Distribution and Global Specialty Products groups.
以非 GAAP 基礎計算,第四季營業利益率為 7.42%,與前一年大致持平,儘管毛利率略有下降,主要原因是全球分銷(Global Distribution)與全球專科產品(Global Specialty Products)事業群的產品組合影響。
Turning to taxes, our effective tax rate for the fourth quarter of 2025 on a non-GAAP basis was 22.7%. This compares with an effective tax rate of 22.0% for the fourth quarter of 2024. For the full year, our non-GAAP effective tax rate was 23.7%.
接著看稅務,2025 年第四季非 GAAP 有效稅率為 22.7%。相較之下,2024 年第四季有效稅率為 22.0%。全年非 GAAP 有效稅率為 23.7%。
Fourth quarter 2025 GAAP net income was $101 million, or $0.85 per diluted share. This compares with prior-year GAAP net income of $94 million or $0.74 per diluted share. Our fourth quarter 2025 non-GAAP net income was $160 million or $1.34 per diluted share. This compares with prior year non-GAAP net income of $149 million or $1.19 per diluted share. Foreign currency exchange favorably impacted our fourth quarter diluted EPS by approximately $0.02 versus the prior year.
2025 年第四季 GAAP 淨利為 1.01 億美元,稀釋後每股盈餘為 0.85 美元。相較之下,前一年 GAAP 淨利為 9,400 萬美元,稀釋後每股盈餘為 0.74 美元。2025 年第四季非 GAAP 淨利為 1.60 億美元,稀釋後每股盈餘為 1.34 美元。相較之下,前一年非 GAAP 淨利為 1.49 億美元,稀釋後每股盈餘為 1.19 美元。與前一年相比,外匯匯率變動對本季稀釋後 EPS 的影響約為正向 0.02 美元。
Adjusted EBITDA for the fourth quarter of 2025 was $291 million compared with fourth quarter 2024 adjusted EBITDA of $270 million or 8.4% growth.
2025 年第四季調整後 EBITDA 為 2.91 億美元,相較 2024 年第四季調整後 EBITDA 的 2.70 億美元,成長 8.4%。
Turning to our sales results, the components of sales growth for the fourth quarter are included in Exhibit A in this morning's earnings release. I'll now provide the primary highlights of the main sales drivers for each reporting segment, starting with Global Distribution and Value-Added Services.
接著看銷售結果,第四季銷售成長的構成已列於今早財報新聞稿的附表 A(Exhibit A)。我將提供各可報導分部主要銷售驅動因素的重點摘要,先從全球分銷與加值服務(Global Distribution and Value-Added Services)開始。
The Global Distribution and Value-Added Services group sales grew by 7.0%. Looking at the drivers of that growth, US Dental Merchandise sales grew 3.6%, including good volume growth driven by the sales initiatives we introduced earlier in the year. US Dental equipment sales grew 10.6%, led by double-digit growth in traditional equipment. Overall demand for equipment remains strong.
全球分銷與加值服務事業群銷售成長 7.0%。就成長動能而言,美國牙科耗材(US Dental Merchandise)銷售成長 3.6%,其中包含由我們年初推出的銷售計畫所帶動的良好銷量成長。美國牙科設備(US Dental equipment)銷售成長 10.6%,主要由傳統設備的雙位數成長帶動。整體設備需求仍然強勁。
US Medical Distribution sales grew 4.9%, reflecting good underlying growth in the business with strong growth in Home Solutions. International Dental Merchandise sales grew 9.2% or 3.8% in constant currencies, driven by sales growth across Southern and Eastern Europe, Germany, Brazil, and Canada.
美國醫療分銷銷售成長 4.9%,反映業務基本面良好成長,其中居家解決方案(Home Solutions)成長強勁。國際牙科耗材(Merchandise)銷售成長 9.2%,或以固定匯率計成長 3.8%,主要由南歐與東歐、德國、巴西及加拿大的銷售成長所帶動。
International dental equipment sales grew 13.9% with constant currency growth of 7.5%, with solid growth in both traditional and digital equipment. Equipment sales growth was especially good in Germany, Brazil, Canada, and Australia. Finally, Global Value-Added services sales grew 9.6% or 8.5% in constant currency, driven by international business solutions.
國際牙科設備銷售成長 13.9%,以固定匯率計成長 7.5%,傳統與數位設備皆有穩健成長。設備銷售成長在德國、巴西、加拿大與澳洲表現尤其亮眼。最後,全球加值服務(Global Value-Added services)銷售成長 9.6%,或以固定匯率計成長 8.5%,主要由國際商業解決方案所帶動。
Turning to the Global Specialty Products group, sales grew 14.6% or 11.1% in constant currency. Our implant and biomaterial business experienced solid growth in the fourth quarter, including double-digit growth in our value implants and mid-single-digit growth in our premium implants. That sales mix of premium and value implants resulted in a lower gross margin compared to the prior year.
接著談全球專業產品(Global Specialty Products)事業群,銷售成長 14.6%,或以固定匯率計成長 11.1%。我們的植體與生物材料業務在第四季呈現穩健成長,包括價值型植體達雙位數成長,以及高階植體達中個位數成長。高階與價值型植體的銷售組合,使得毛利率較去年同期為低。
We also had strong results in the Global Technology Group with total sales growth of 8.4% or 7.6% in constant currency. In the US, sales growth was driven by practice management software with double-digit growth in Dentrix Ascend. Internationally, sales growth was driven by our Dentally, cloud-based practice management software product.
全球科技事業群(Global Technology Group)也有強勁表現,總銷售成長 8.4%,或以固定匯率計成長 7.6%。在美國,銷售成長主要由診所管理軟體帶動,其中 Dentrix Ascend 達雙位數成長。在國際市場,銷售成長則由我們的 Dentally 雲端診所管理軟體產品所帶動。
From the restructuring program announced in August of 2024, the company recorded restructuring expenses of $23 million or $0.12 per diluted share during the fourth quarter of 2025. For the full year, restructuring expenses were approximately $105 million or $0.59 per diluted share.
針對 2024 年 8 月宣布的重整計畫,公司於 2025 年第四季認列重整費用 2,300 萬美元,或每股稀釋後盈餘 0.12 美元。全年重整費用約為 1.05 億美元,或每股稀釋後盈餘 0.59 美元。
Regarding the value creation initiatives announced last quarter, we continue to expect to deliver over $200 million of operating income improvement over the next few years through both cost savings and capturing incremental gross margin opportunities. These projects include gross profit optimization such as pricing and accelerating corporate brand sales as well as initiatives to lower our cost to serve while further enhancing customer satisfaction.
關於上季宣布的價值創造(value creation)計畫,我們仍預期在未來幾年透過成本節省與掌握額外毛利機會,使營業利益改善超過 2 億美元。這些專案包括毛利優化(例如定價與加速企業品牌銷售),以及降低服務成本、同時進一步提升客戶滿意度的各項措施。
We plan to centralize certain support services, implement process automation and AI tools, and further leverage our scale to reduce indirect procurement costs. We expect these initiatives to achieve annual run rate operating income improvement of over $125 million by the end of 2026.
我們計畫將部分支援服務集中化,導入流程自動化與 AI 工具,並進一步運用規模優勢以降低間接採購成本。我們預期這些措施在 2026 年底前可達成年度化(run rate)營業利益改善超過 1.25 億美元。
During the fourth quarter of 2025, the company repurchased approximately 2.8 million shares of common stock at an average price of $71.10 per share for a total of $200 million. At fiscal year end, we had approximately $780 million authorized and available for future stock repurchases.
在 2025 年第四季,公司以每股平均 71.10 美元回購約 280 萬股普通股,總金額 2 億美元。於會計年度期末,我們仍有約 7.8 億美元的股票回購授權額度可供未來回購使用。
Turning to our cash flow.
接著談我們的現金流。
We generated operating cash flow of $381 million in the fourth quarter of 2025. This compares with operating cash flow of $204 million in the fourth quarter of 2024 and was driven by working capital management.
我們在 2025 年第四季產生營運現金流 3.81 億美元。相較之下,2024 年第四季營運現金流為 2.04 億美元,主要受惠於營運資金管理。
Turning to our 2026 financial guidance. At this time, we are not able to provide without unreasonable effort, an estimate of restructuring costs related to ongoing value creation initiatives. Therefore, we are not providing GAAP guidance. Our 2026 guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs and other items described in our press release.
接著談 2026 年財務指引。目前我們無法在不付出不合理努力的情況下,估計與持續進行的價值創造計畫相關的重整成本。因此,我們不提供 GAAP 指引。我們的 2026 年指引係針對目前持續營運(continuing operations),不包含重整費用及相關成本,以及新聞稿中所述的其他項目之影響。
Guidance assumes stable dental and medical end markets during the year and is supported by initiatives outlined in our strategic plan. We expect these initiatives will support our long-term financial goals. Our guidance also assumes that foreign currency exchange rates will remain generally consistent with current levels and that the effects of tariffs can be mitigated. Our 2026 sales growth is expected to be 3% to 5% over 2025.
指引假設年度內牙科與醫療終端市場維持穩定,並由我們策略計畫中所列的各項措施支撐。我們預期這些措施將支持我們的長期財務目標。指引亦假設外匯匯率大致維持在目前水準,且關稅影響可被緩解。我們預期 2026 年銷售成長率相較 2025 年為 3% 至 5%。
For 2026, we expect non-GAAP diluted EPS attributable to Henry Schein Inc. to be in the range of $5.23 to $5.37 reflecting growth of 5% to 8% compared to 2025 non-GAAP diluted EPS of $4.97. Guidance assumes lower remeasurement gains in 2026 than in 2025. We are assuming an estimated non-GAAP effective tax rate of approximately 24%. Given the implementation schedule for the value creation initiatives, we expect earnings growth to be more heavily weighted towards the second half of the year. Our 2026 adjusted EBITDA is expected to grow in the mid-single-digits versus 2025 adjusted EBITDA of $1.1 billion.
2026 年,我們預期歸屬於 Henry Schein Inc. 的非 GAAP 稀釋後每股盈餘(EPS)介於 5.23 至 5.37 美元,較 2025 年非 GAAP 稀釋後 EPS 4.97 美元成長 5% 至 8%。指引假設 2026 年的重新衡量收益(remeasurement gains)低於 2025 年。我們假設非 GAAP 有效稅率約為 24%。考量價值創造計畫的導入時程,我們預期獲利成長將較偏重於下半年。我們預期 2026 年調整後 EBITDA 相較 2025 年調整後 EBITDA 11 億美元,將呈中個位數成長。
With that, I'll now turn the call back to Stanley.
接下來,我把電話交回給 Stanley。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Ron. We are, of course, ready, operator, to answer questions from investors, so please go ahead, operator.
謝謝你,Ron。當然,我們已準備好回答投資人的提問,接線員,請開始。
Operator
Operator
(Operator Instructions)
(接線員指示)
Jeff Johnson, Baird.
Jeff Johnson,Baird。
Jeffrey Johnson - Analyst
Jeffrey Johnson - Analyst
Stan, I'm sure you're growing tired of the accolades, so I will just say, congratulations on a fantastic career and, we'll miss hearing you on the calls every quarter.
Stan,我相信你已經聽膩了各種讚譽,所以我就只說:恭喜你有一段精彩的職涯,我們會想念每一季在電話會議上聽到你的聲音。
I was hoping I could maybe start, Ron, on guidance if possible and sorry to start there, Stan, as opposed to throwing it to you for a high-level question, but a couple things just on the operating income improvement plan, the $125 million run rate that you're talking about, Ron, exiting 2026. Should we gate that, kind of build that in a sequential basis kind of on a steady state growing it consistently throughout the year by quarter, and then from a year-over-year perspective, in '27, how much of that do you think, could flow through to the bottom line?
如果可以的話,我想先從指引開始問,Ron,也抱歉先從這裡開始,Stan,而不是先丟給你一個高層次的問題。不過有幾點是關於營業利益改善計畫:你提到在 2026 年底退出時(exiting 2026)年度化(run rate)達 1.25 億美元,Ron。我們是否應該把它視為一個按季度逐步建立、相對穩定且連續的成長軌跡?另外,從年對年角度來看,在 2027 年你認為其中有多少可能會反映到最終獲利(bottom line)?
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Sure Jeff, I think that the -- as you can appreciate, these initiatives are in their -- it's still somewhat in the early stages and that's why we're -- what I said on the guidance that we expect the earnings growth to be more heavily weighted to the back half of the year is a reflection as well of the benefits that we ultimately get from value creation.
當然,Jeff。我想你也能理解,這些措施仍處於——仍算是早期階段,這也是為什麼我在指引中提到,我們預期獲利成長會更偏重於下半年,這同樣反映了我們最終從價值創造中取得的效益。
So I think it's by no means linear. I do think that as we make investments in the first half of the year and continue to make some investments over the course of the year, that'll be reflected in our results, but we've take that into consideration with the guidance.
所以我認為這絕非線性。我確實認為,當我們在上半年進行投資,並在全年持續投入一些投資時,這會反映在我們的業績中,但我們已在指引中將此納入考量。
In terms of the $125 million, and what we will -- how that impacts 2027, that remains to be seen at this point in time. We'll have to see just where we are on the initiatives, what else is happening with the business in terms of where we need to make investments and how much of that will fall through in 2027 we'll be able to address that.
至於 1.25 億美元,以及它將如何影響 2027 年,目前仍有待觀察。我們必須看看這些措施推進到什麼程度、業務端還發生了哪些事情(例如我們需要在哪些方面投資),以及其中有多少會在 2027 年落到損益表上;屆時我們會再做說明。
Operator
Operator
Allen Lutz, Bank of America.
Allen Lutz,美國銀行(Bank of America)。
Allen Lutz - Analyst
Allen Lutz - Analyst
One for Ron here on the really strong growth in specialty value implants as you mentioned, up double-digits, but also premium implants were up mid-single-digits, which I think is an acceleration over the past couple of quarters.
我有一題想問 Ron:你提到專業領域的價值型植體成長非常強勁、達雙位數;同時高階植體也有中個位數成長,我認為這相較過去幾季算是加速。
Can you talk a little bit about what you're seeing there in terms of pricing both on the value and the premium side? Is that evolving at all? And then how to think about price growth as a contribution or lever within this business in 2026?
你能否稍微談談你們在定價方面看到的情況,包括價值端與高端(premium)端的定價?這方面有在演變嗎?另外,該如何看待在2026年,價格成長作為這項業務的貢獻或槓桿?
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Certainly, the -- we're -- as we mentioned, we were especially pleased with the growth we saw in Europe. We had good growth at Biotech, we had good growth in Germany, and the value implants are becoming a bigger part of the portfolio for us.
當然——我們——如同我們提到的,我們對歐洲所看到的成長特別滿意。我們在Biotech有不錯的成長,在德國也有不錯的成長,而價值型植體正逐漸成為我們產品組合中更大的一部分。
From a pricing perspective, I don't think there's anything there that's unusual from a pricing perspective. I would say that we're very well priced within the market and I don't believe there was anything that would be -- I would consider to be unusual in terms of price increases or price benefit within the category.
從定價角度來看,我不認為在定價方面有任何不尋常之處。我會說我們在市場中的定價非常到位,而且我不認為在該品類中有任何——我會認為——在漲價或價格紅利方面不尋常的情況。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
I think that's correct. The issue is that there's been a movement, a mix within our portfolio towards the brands that Ron just identified. The Camlog brand in Germany, for example, which is our largest market for that product, has stable pricing yet we continue to gain market share, so I don't think there's particular pressure on our main premium brands which do sell a little bit less than some of the other major brands and this is all a mixed shift towards faster growth by these companies we've invested in the last couple of years that are all doing well.
我認為這是正確的。問題在於,我們的產品組合內部出現了朝向Ron剛剛指出的品牌的移動與組合變化。例如在德國的Camlog品牌——那是該產品對我們而言最大的市場——定價穩定,但我們仍持續提升市占率,所以我不認為我們主要的高端品牌面臨特別的壓力;這些高端品牌的售價確實比其他一些主要品牌略低一些,而這一切都反映出組合正轉向我們過去幾年投資、且表現都很好的公司所帶來的更快成長。
Operator
Operator
Jason Bednar, Piper Sandler.
Jason Bednar,Piper Sandler。
Jason Bednar - Analyst
Jason Bednar - Analyst
Congrats on the close here to '25. I'm going to ask a multi-part question here just big picture in the dental market, Stan.
恭喜你們在接近25年收官之際的表現。我想問一個多段式的問題,從牙科市場的大方向來看,Stan。
It just really seems like the market took a step forward in the fourth quarter. I think we're all seeing that results are looking better across the board for you and your partners. Can you speak to the durability of that performance? Sounds like it's continued into January, but you're often a step closer to the customer. You're interacting with them on a more frequent, regular basis than even your manufacturing partners are.
看起來市場在第四季確實向前邁進了一步。我想我們都看到你們以及你們合作夥伴的整體表現都更好了。你能談談這種表現的持續性(耐久度)嗎?聽起來這種趨勢延續到一月,但你們通常更貼近客戶。你們與客戶互動的頻率與規律性,甚至比你們的製造合作夥伴還高。
Just, do you sense the market's getting its foot back or footing back in terms of the patient traffic through offices, consumer spending on the higher end categories, dentists spending on equipment, I guess what are you seeing with your backlog? Just it was -- I guess the genesis of the question, is there anything unique in the fourth quarter that would suggest that better revenue growth wouldn't persist throughout 2026 here?
你是否感覺市場在病患到診量、消費者在高端品類的支出、牙醫在設備上的支出等方面,正在重新站穩腳步?另外你們的訂單積壓(backlog)情況如何?我想這個問題的出發點是:第四季是否有任何特殊因素,會讓人覺得較佳的營收成長在2026年不會持續?
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
So thanks for that question, Jason. It's a very important question.
謝謝這個問題,Jason。這是一個非常重要的問題。
I would say the markets are stable, certainly in the US, we have data from our Henry Schein One claims processing. So essentially it is a stable market leaning, I would say positively. There is good feeling amongst dentists that investing in newer technology, whether it's scanners or AI or simply upgrading their practice management systems and connecting those practice management systems to hardware, chairs, units, lights, imaging, et cetera. That whole trend is there. And I think it's good. The market is good in the US and international is mixed.
我會說市場是穩定的,至少在美國是如此;我們有來自Henry Schein One理賠處理的數據。所以本質上這是一個穩定、我會說略偏正向的市場。牙醫對於投資新技術的感受不錯,不論是掃描器、AI,或只是升級他們的診所管理系統,並把這些管理系統與硬體——牙科椅、治療單元、燈具、影像設備等等——連接起來。整體趨勢都在。而我認為這是好的。美國市場表現不錯,國際市場則是好壞不一。
But I think a lot of this has to do with Henry Schein as well. We were hunkered down a little bit, a lot actually on the cyber recovery. Our people were internally focused on keeping current customers and not going out aggressively. In the second quarter, we felt very good that we dealt with the past, and we started being aggressive going out, adding resources to our sales organization, bringing online for digital offerings, so I think it's a combination of dentists feeling good about their practices, patient traffic being okay, meaning slightly positively in the US, and our sales organization having the ability to go and explain to dentists why investing in these various newer technologies is good for their practice.
但我認為其中很大一部分也與Henry Schein自身有關。我們之前有點——其實是相當——因為網路事件復原而採取保守姿態。我們的同仁當時更專注於內部,維繫既有客戶,而不是積極對外拓展。到了第二季,我們覺得已經很好地處理完過去的問題,於是開始積極出擊,為銷售組織增加資源,並讓數位產品/服務上線,所以我認為這是多重因素的結合:牙醫對其診所經營感覺良好、病患流量尚可(在美國略偏正向),以及我們的銷售團隊有能力去向牙醫說明,為何投資這些較新的技術對他們的診所是有利的。
So to some extent we are expanding the market within our own customer base, but generally it's a positive feeling for those that were in Chicago. If you walked on the floor, people were smiling and went to the Schein booth, particularly smiling. So I think that things are stabilized. I hope not to use the word cybersecurity. I hope our team doesn't use that again because that way behind us and the team is very positive, very excited.
因此在某種程度上,我們正在我們既有客戶群中擴大市場,但整體而言,對於那些在芝加哥的人來說,氛圍是正向的。如果你走在展場裡,你會看到大家都在微笑;走到Schein的攤位,大家更是笑得特別開心。所以我認為情況已經穩定下來。我希望不要再用「網路安全」這個詞。我也希望我們團隊不要再提這個,因為那已經是很久以前的事了;團隊非常正向、非常興奮。
We are winning in the marketplace, in a marketplace that is stable to leaning positively and many of the markets abroad are also similar. Look at Brazil, for example, the German market is a lot more positive on the equipment side, so it's a positive environment from a market point of view, but I think most of our success is from our team's excitement in winning in the marketplace and being back to where we were before October of '23 when we had the cyber incident.
我們正在市場上取得勝利;而這個市場是穩定、略偏正向的,海外許多市場也類似。例如看看巴西;德國市場在設備端也更為正向,所以從市場角度來看是正向的環境,但我認為我們大部分的成功來自團隊在市場上取勝的熱情,以及回到我們在2023年10月發生網路事件之前的狀態。
Operator
Operator
John Stansel, JP Morgan.
John Stansel,JP Morgan。
John Stansel - Analyst
John Stansel - Analyst
Just wanted to hone in on the cadence through the year, particularly around the $125 million run rate contribution from the value creation initiatives on. What I think I heard from you, Ron, was that there would be implementation costs in the first half of the year or early in the year. Is there a way to think about this? This is actually potentially a bit of a headwind early on. And if that's right, is it still fair to say that it's a net benefit, you don't -- you get some improvement in the back half, netting all that out to still be kind of a benefit for the full year.
我想聚焦在全年節奏上,特別是價值創造計畫帶來的1.25億美元年化(run rate)貢獻。Ron,我理解你剛才的意思是,上半年或年初會有一些導入/落地成本。有沒有一種方式可以這樣思考?也就是說,這在年初其實可能會形成一些逆風。如果是這樣,那是否仍然可以說它是淨受益:你們在下半年會看到一些改善,整體抵消後,全年仍然算是帶來好處?
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Yeah, John, I mean, the expectation for the full year is clearly there will be a net benefit from the initiatives. Within the quarters, you could get -- some lumpiness depending on the timing of some of the investment, but there will be -- we're confident and we'd be disappointed if we didn't have a net benefit over the course of the year from these but that benefit will be more heavily weighted to the second half of the year.
是的,John,我的意思是,對於全年而言,我們的預期很明確:這些計畫將帶來淨受益。在各季度之間,可能會因為某些投資時點而出現——一些不均勻(lumpiness)。
Operator
Operator
Kevin Caliendo, UBS.
Kevin Caliendo,UBS。
Kevin Caliendo - Analyst
Kevin Caliendo - Analyst
Just two quick ones.
兩個很快的問題。
The lower remeasurement '26, you described it as lower. Is it materially lower? Like, just from a modeling perspective, how should we think about versus the $0.23?
你提到26年的重估(remeasurement)會更低,你形容為較低。那是顯著更低嗎?就建模角度來看,相對於0.23美元,我們應該怎麼看待?
And then the second one is more about the equipment you called out that there was a benefit from promotions. Obviously traditional equipment was up double-digit in 4Q. Is that an assumed run rate now or was that sort of a one-time benefit? Can you just talk about what happened, how meaningful it was, and how we should think about traditional equipment growth in '26? Thanks, guys.
第二個問題是關於設備:你提到促銷帶來了一些助益。顯然傳統設備在第四季是雙位數成長。這現在是你們假設的常態年化水準(run rate)嗎?還是某種一次性的助益?你能談談發生了什麼、影響有多大,以及我們應該如何看待26年傳統設備的成長嗎?謝謝各位。
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Yeah, I'll start with some commentary on the remeasurement gain, Kevin, and then Stanley can talk a little more about equipment, but as you're aware that the portfolio approach to growth has included taking a minority stake in certain companies and in some cases extending that investment to a controlling interest when we believe there's a strategic reason to do so and there are a couple of situations where we are contemplating transactions that could result in a range of remeasurement gain outcomes in 2026 and we've taken this range into consideration when setting our guidance.
Kevin,我先就重新計量收益(remeasurement gain)做一些評論,接著 Stanley 可以再多談一點設備方面。不過如你所知,我們以投資組合方式推動成長的策略,包括在某些公司取得少數股權,而在我們認為有策略性理由時,也會在部分情況下將投資擴大至取得控制性權益。目前有幾個情境我們正在考慮可能的交易,這些交易在 2026 年可能導致不同幅度的重新計量收益結果;我們在設定指引時已將這個區間納入考量。
But what we said is the EPS guidance assumes remeasurement gains will be lower in '26 than it was in '25. As you can appreciate, it's difficult to gauge sometimes what the benefit of these will be, but we do expect -- we're pretty confident it will be less than what we had in 2025.
但我們所說的是,EPS 指引假設 2026 年的重新計量收益將低於 2025 年。如你所理解的,有時很難衡量這些收益能帶來多少好處,但我們預期——我們相當有信心——它會少於我們在 2025 年所取得的水準。
Stanley, if you want to address the equipment question.
Stanley,如果你想回應設備的問題。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Ron. I think that's great.
謝謝你,Ron。我覺得這很好。
On the equipment side, I just want to be careful not to indicate that we had massive promotions. We did not. It was a normal year end and of course the fourth quarter is a quarter where dentists are investing in the practice for tax reasons so that the whole year they've been thinking about buying a piece of equipment or maybe addressing an expanded room or something operatory and you know of course our salespeople encourage them to close on that and have it installed before the year end because it's tax beneficial.
在設備方面,我只想小心不要讓人以為我們做了大規模促銷。我們沒有。那就是正常的年終情況;當然第四季是牙醫基於稅務因素而投資診所的一季,所以他們整年都在考慮要不要買一台設備,或是可能要擴增一間診間之類的治療室(operatory)。你也知道,我們的業務人員會鼓勵他們在年終前完成成交並安裝好,因為在稅務上更有利。
I will say that there are a few manufacturers of equipment that excited our organization. A couple of them maybe had high priced products per unit. And was, of course, had extra features maybe viewed by dentists as better products, better to invest in those products, and I would say we have promotions of that kind where manufacturers, their field organization, and our organization worked very well together on promotions specific to a product or category or to a manufacturer.
我會說,有幾家設備製造商讓我們組織感到很振奮。其中有幾家可能單台產品的單價較高。而且當然也有額外功能,牙醫可能會視為更好的產品、更值得投資。我會說,我們有這類型的促銷:製造商、他們的前線團隊以及我們的團隊,在針對特定產品或品類或特定製造商的促銷上配合得非常好。
But these were not -- these are not promotions that pulled from one quarter to the other going into the first quarter. I think we mentioned in our last call that our backlog was good going out, it remains good. The momentum is good, and again it goes back to our sales people. Both the generalists, the specialists, the equipment people just feeling good. They were back in the market, attacking the market, gaining market share in an environment where dentists are feeling pretty good. And so I think it's just the dynamics, and we're very pleased with the dynamics and view this as an ongoing opportunity for Henry Schein.
但這些並不是——這些不是那種把需求從一個季度拉到另一個季度、提前到第一季的促銷。我想我們在上次電話會議提到,我們期末的未交訂單(backlog)狀況良好,現在仍然良好。動能很不錯,而這再次回到我們的業務人員。不論是通才型、專科型,或是設備團隊,都感覺很好。他們回到市場、積極開拓市場,在牙醫感覺相當不錯的環境下提升市占。所以我認為這就是市場動態;我們對這些動態非常滿意,並將其視為 Henry Schein 的一項持續性機會。
Operator
Operator
Jonathan Block, Stifel.
Jonathan Block,Stifel。
Joseph Federico - Analyst
Joseph Federico - Analyst
Joe Federico on for John. Thanks for taking the questions.
我是代替 John 的 Joe Federico。謝謝讓我提問。
Maybe just to move back to the impressive Specialties growth in the quarter. Seemingly driven by global double-digit percent implant sales. How do you view the sustainability of that implant performance? I know it's likely not double-digit every quarter, but should we just view that segment, the specialty segment as kind of a high single-digit growth profile going forward for the near future, and also any specific color on US implant performance would be helpful as well.
也許回到本季令人印象深刻的專科(Specialties)成長。看起來是由全球雙位數百分比的植牙(implant)銷售所帶動。你們如何看待這樣的植牙表現的可持續性?我知道不太可能每一季都是雙位數,但我們是否可以把該分部——專科分部——在可見的未來視為大約高個位數成長的輪廓?另外,也希望能提供一些關於美國植牙表現的具體說明。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Ron can address the implant market because we have -- we gave a range and I think the market is not growing as well as we thought -- as it was in a few years ago, but Ron will address the market.
Ron 可以談談植牙市場,因為我們——我們給了一個區間,而且我認為市場成長沒有我們想的那麼好——不像幾年前那樣,但 Ron 會說明市場情況。
Yeah, we had a very good quarter. Our European, particularly our German business is doing well. It's been doing well for a long time. I think we're now the number one provider of dental implants certainly by units in Germany and that market has very good momentum. No one can say that we have great particular quarters. But I think it's a solid business. We've got a great product offering, new introductions of products and a great team. The various discount lines if you will or value lines depending on how you want to view it of S.I.N. of our Biotech German product and the dentist and even within BioHorizons, the value line are all doing very well.
是的,我們本季表現非常好。我們的歐洲業務,特別是德國業務表現良好。它長期以來一直表現不錯。我想我們現在在德國就出貨量(units)而言,肯定是牙科植體的第一大供應商,而該市場動能非常好。沒有人能說我們每一季都會特別突出。但我認為這是一門穩健的業務。我們有很好的產品組合、新產品導入,以及很棒的團隊。不論你稱之為折扣線(discount lines)或價值線(value lines),我們的 S.I.N.、Biotech 的德國產品,以及甚至在 BioHorizons 之內的價值線,都表現得非常好。
I think the implant market is stable. Leaning positively, more stable in the US than it's been in a while. Henry Schein does not really operate in a very expensive implant category in the US. Of course, BioHorizons has a product offering, but we're more focused on the practice that is dealing with middle income DSOs and so we didn't have the significant decrease that maybe some others did. But generally it's a pretty stable market. The US is not as robust as other parts of the world. We were focused on a new product introduction this year. And I think we'll be more aggressive next year, but I don't think we can give you specific thoughts on the high end of growth in '26, but Ron will give you specifics on the range that we're talking about.
我認為植牙市場是穩定的。偏向正面,在美國比過去一段時間更穩定。Henry Schein 在美國其實不太涉足非常昂貴的植體類別。當然 BioHorizons 有產品組合,但我們更聚焦於服務中等收入的 DSO 診所,因此我們沒有像某些同業那樣出現顯著下滑。但整體而言,這是一個相當穩定的市場。美國不像世界其他地區那麼強勁。我們今年聚焦於新產品導入。我想明年我們會更積極,但我不認為我們能就 2026 年成長的高端給出具體看法;不過 Ron 會就我們所談的區間提供更具體的說明。
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Certainly, so, Joe, I think you can kind of dissect the implant market a couple of different ways. If you look at the kind of outside US versus inside US market, we did see better growth outside the US, and then we mentioned that in the prepared remarks that our subsidiary in France Biotech and Camlog, both had very good growth and I really attribute that to good management and execution, good -- just they're doing a very good job of getting some additional market share there. Our assumption has always been that specialty markets should grow in that 5% to 8% market range. I don't think they are right now. Perhaps there are some pockets of the world where they are growing 5% to 8%. But inside the US, I don't think it's at 5% to 8%. We're seeing still something probably less than -- definitely less than 5% in terms of market growth in the US.
當然,所以 Joe,我想你可以用幾種不同方式來拆解植牙市場。如果你看美國以外與美國境內的市場,我們確實看到美國以外的成長較佳;我們也在事先準備的講稿中提到,我們在法國的子公司 Biotech 以及 Camlog 都有非常好的成長,我把這歸因於良好的管理與執行力——他們在那裡取得更多市占做得非常好。我們一向的假設是,專科市場應該在 5% 到 8% 的市場成長區間。我不認為目前是這樣。也許世界上有些區域確實在 5% 到 8% 成長。但在美國境內,我不認為有 5% 到 8%。我們看到美國的市場成長仍可能低於——肯定低於 5%。
And then if you also dissect it by looking at premium versus value in the US, and we mentioned on the call that we did launch the S.I.N. US value implant in the US in the fourth quarter, and we have a lot of optimism in terms of what the contribution we could get from that product in terms of it improving our growth in the US going forward in '26, so, like Stanley said, it's difficult to determine where that high end is where this growth could be, but we do like the momentum we have coming out of '25 and '26 with the broader category.
另外,如果你也用美國市場的高端(premium)與價值(value)來拆解,我們在電話會議中提到,我們在第四季於美國推出了 S.I.N. 的美國價值型植體(value implant)。我們對該產品在 2026 年往後、在提升我們美國成長方面可能帶來的貢獻相當樂觀。所以,如同 Stanley 所說,很難判斷成長的高端會落在哪裡,但我們確實喜歡我們在 2025 年末以及 2026 年、在更廣泛品類上所展現的動能。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Ronald. So the end of business is quite stable, not yet the market per se is growing, but we are doing quite well. Gaining some market share, the orthopedic business has also got certain momentum that is very nice and orthodontics is very small. But we're moving that product through our distribution channel, not investing a huge amount in specialty salespeople, but offering an alternative of traditional orthodontic products at a reasonable price, a value product, and so we arenât losing money in that field.
謝謝你,Ronald。所以終端業務相當穩定,市場本身尚未明顯成長,但我們表現得相當好。我們正在取得一些市占;骨科(orthopedic)業務也有相當不錯的動能,而齒顎矯正(orthodontics)規模非常小。但我們透過我們的配銷通路推動該產品,並未在專科業務人員上投入大量資源,而是以合理價格提供傳統矯正產品的替代方案——一個價值型產品——因此我們在該領域並沒有虧損。
We had a bit of a challenge with computers during the cyber incident and overall the specialty business is doing well and also that's on our own brands, specialty products but also on our private brand, our corporate brand products where we have products OEM manufactured for us, that business is growing at a more rapid rate to our -- the core national brand business. Of course we work very well with certain national brand manufacturers, but there are many products where the product line is really generic today and in those cases where we can provide value to our customers, we are, and that's growing at a much faster rate.
在網路資安事件期間,我們在電腦系統方面確實遇到了一些挑戰;整體而言,專科業務表現良好。此外,這也反映在我們自有品牌的專科產品上,同時也反映在我們的自有品牌/企業品牌產品上——也就是由OEM為我們代工生產的產品;該業務相較於我們的——核心全國性品牌業務,正以更快的速度成長。當然,我們與部分全國性品牌製造商合作得非常順暢,但也有許多產品線如今本質上相當通用;在這些情況下,只要我們能為客戶提供價值,我們就會這麼做,而這部分的成長速度也快得多。
Operator
Operator
Elizabeth Anderson, Evercore ISI.
Elizabeth Anderson,Evercore ISI。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Congrats Stanley and I'm looking forward to working with Fred going forward.
恭喜你,Stanley,我也期待未來能與Fred合作。
Maybe a combo short-term, long-term question. Just to confirm as per usual, none of the future repo with the authorization is included in the guidance range you just gave.
也許是一個短期與長期結合的問題。只是想確認一下,照慣例,你們剛剛給出的指引區間並未包含任何在授權額度下、未來可能進行的回購(repo)。
And then secondarily, can you talk a little bit more on the gross margin? I think you guys called out pricing and private label as opportunities I'm assuming for '26 and going forward. So how do you think about what the sort of 2026 opportunities are there versus longer-term? Thank you very much.
第二個問題是,你們能否再多談一點毛利率?我記得你們提到定價與自有品牌(private label)是機會,我猜這是針對2026年以及之後。那你們如何看待2026年的機會相較於更長期的機會?非常感謝。
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
Regarding the repurchases, Elizabeth, we -- our guidance assumes a relatively stable stock count during the year but as you can appreciate, we'll be assessing the stock repurchase opportunities as the year progresses and if it has a material impact, we'll be sure to communicate that.
關於回購,Elizabeth,我們——我們的指引假設今年的流通股數相對穩定;但如你所理解的,我們會隨著年度推進評估股票回購的機會,若對結果有重大影響,我們一定會對外溝通。
In terms of the margin and the contribution from private label, private label continues to grow at a pace faster than our branded merchandise, so we are getting some contribution to -- favorable contribution to the margin from that. There's still some -- you get some pricing pressure in certain categories. We've talked about gloves in the past and other areas but so it -- but broadly speaking, the private label does provide us with some margin expansion and we do believe and part of our value creation initiative is how do we -- how can we expand those margins potentially even through accelerating the growth of some of those private label categories.
就毛利率以及自有品牌的貢獻而言,自有品牌持續以快於我們品牌商品的速度成長,因此在毛利率上對我們有一些——正向的貢獻。某些品類仍然會有一些——定價壓力。我們過去談過手套以及其他領域;所以——但整體來看,自有品牌確實為我們帶來一定的毛利率擴張。我們也相信,且作為我們價值創造計畫的一部分,我們正在思考如何——如何透過加速部分自有品牌品類的成長,來進一步擴大這些毛利率。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
But to be clear, Elizabeth, we are working very well today with many of our national brand suppliers who understand the value Henry Schein brings, we did have some challenges because of the cyber incident, and we're back in the market, so they're working with us.
但要說清楚,Elizabeth,我們目前與許多全國性品牌供應商合作得非常好,他們理解Henry Schein所帶來的價值;我們確實因網路資安事件遇到一些挑戰,但我們已回到市場上,所以他們也正在與我們合作。
On the other hand, there are many items I wouldn't call them commodities because some of them are better than commodities â the Henry Schein brand is simply another brand but it is a high-quality brand and attracts customers because of the quality but also because of the price, the whole value proposition, and that's doing very well. It's a stated goal of ours and we're doing quite well in that regard and of course that carries a higher margin, a lower price but a higher margin with absolute dollar addition to the bottom line.
另一方面,有許多品項我不會稱之為大宗商品,因為其中一些比大宗商品更好——Henry Schein品牌只是另一個品牌,但它是高品質品牌,因為品質、也因為價格與整體價值主張而吸引客戶,而這部分表現非常好。這是我們明確的目標之一,而且我們在這方面做得相當不錯;當然,這也帶來較高的毛利率——價格較低但毛利率較高,並且以絕對金額為底線帶來增量貢獻。
Operator
Operator
Michael Cherny, Leerink Partners.
Michael Cherny,Leerink Partners。
Michael Cherny - Analyst
Michael Cherny - Analyst
Maybe if we can dig in a little bit more on implied margins relative to what you recognized in the quarter. Fully understand there's a lot of moving pieces, fully understand the operational improvements you expect to ramp over the course of the year, but what are you seeing relative to your underlying business on the margin side? I know there's been some questions on price and there's obviously a dynamic on mix, but how are we thinking about the core underlying margins for the business before you layer on the remeasurement dynamics, the operational benefits, and other moving pieces to the P&L?
也許我們可以再深入一點,談談你們指引中隱含的利潤率,相對於你們在本季認列的水準。我完全理解有很多變動因素,也理解你們預期營運改善會在全年逐步爬坡,但就毛利率而言,你們在基礎業務上看到的是什麼?我知道市場對價格有一些疑問,組合也顯然在變動;但在把重新衡量(remeasurement)因素、營運效益以及其他損益表上的變動因素加進來之前,我們應該如何看待公司核心基礎業務的毛利率?
Ronald South - Chief Financial Officer, Senior Vice President
Ronald South - Chief Financial Officer, Senior Vice President
I think that a lot of moving parts when you talking about our margins because of the -- when you look at the business as a whole, we are experiencing some product mix dynamics, for example, within the specialty group. We mentioned earlier that value is growing faster. Value implants are growing faster than premium implants, for example. They do get a slightly lower gross margin. And that you know will put a little bit of pressure in terms of gross margin percentage, but it does create gross profit dollar growth for us which is very important for us.
我認為談到我們的毛利率時,確實有很多變動因素,因為——當你從整體業務來看,我們正經歷一些產品組合的變化,例如在專科事業群內。我們先前提到,價值型(value)產品成長更快。例如,價值型植體的成長速度快於高階植體。它們的毛利率確實略低一些。這會在毛利率百分比上帶來一些壓力,但它也為我們帶來毛利(以金額計)的成長,而這對我們非常重要。
I think within the broader distribution, there's always going to be customer mix. I mean, we have a very strong portfolio of DSO customers. DSO customers do get a slightly better margin, but we can deliver to them more efficiently. So that's an important part of the portfolio and an important part of the business and their growth -- the growth of those DSOs benefits us as well.
我認為在更廣泛的通路配送業務中,客戶組合也總是會變動。我的意思是,我們擁有非常強的DSO客戶組合。DSO客戶的毛利率確實會略好一些,但我們能更有效率地為他們配送。因此,這是我們組合中很重要的一部分,也是業務中很重要的一部分,而這些DSO的成長——它們的成長也同樣讓我們受益。
So while we were -- we want to stay focused on gross margin percentage improvements, and that's a very important value creation initiative for us. Growing gross profit dollars is equally important, and so to the extent that we can expand sales and grow gross profit dollars as well is always going to be a priority for us.
因此,雖然我們——我們希望持續聚焦於毛利率百分比的改善,這也是我們非常重要的價值創造計畫;但毛利金額的成長同樣重要。所以,只要我們能擴大銷售並同時提升毛利金額,這一直都會是我們的優先事項。
In terms of what then falls out and for operating margin, hence the -- a lot of the G&A expense initiatives that we have in place to deliver product more efficiently to support the business more efficiently, and we believe that that'll show up in -- those benefits will begin to show up towards the back half of the year and ultimately, should see some acceleration and improvements in operating margin.
至於接下來反映到營業利益率的部分,因此——我們推動了許多G&A費用的計畫,以更有效率地交付產品、更有效率地支援業務;我們相信這些效益將在——今年下半年開始顯現,並且最終應該會看到營業利益率出現一些加速與改善。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
It's a matter of mix and at the end of the day, our BOLD+1 strategic plan is what drives us and the idea is to move towards high-growth, high-margin businesses, higher gross profit, higher operating income and we stated early on in the call that the direction of the business, the whole area of high growth, high margin businesses, the specialty areas, the value-added services are growing quite nicely as well as the private brands, so it's hard to get the exact number -- predict the exact number in a quarter, the direction the business is moving towards higher growth, higher margin mixed businesses.
這歸根究柢是組合的問題;而在最後,我們的BOLD+1策略計畫是驅動我們的核心,理念是朝向高成長、高毛利的業務前進,帶來更高的毛利、更高的營業利益。我們在電話會議一開始就提到,業務的方向——整體朝向高成長、高毛利的業務領域前進:專科領域、加值服務也都成長得相當不錯,自有品牌亦然;因此很難在單一季度——精準預測確切數字,但業務的方向正朝向更高成長、更高毛利的組合型業務。
Operator
Operator
Brandon Vazquez, William Blair.
Brandon Vazquez,William Blair。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
I'll maybe ask two brief ones to close us out here, maybe a little macro. First, on the medical side, there's a lot of chatter in the MedTech world, especially about volumes of procedure volumes through the first quarter and then it through 2026 since you guys are kind of tied to the dental market volumes, I'd just be curious on how are things progressing so far in early 2026 in terms of volumes. People are a little worried about ACA subsidies going away and that might lower procedure volumes. There's some storms. There's flu season, things like that.
我可能用兩個簡短問題作結,可能偏宏觀一點。第一個,在醫療端,MedTech圈子裡有很多討論,特別是關於第一季的手術量,以及延伸到2026年的趨勢;由於你們某種程度上與牙科市場的量能相關,我想了解一下,2026年初到目前為止,在量能方面進展如何。大家有點擔心ACA補貼可能取消,這可能會降低手術量。還有一些風暴。還有流感季之類的因素。
That's the first one, and I'll just ask the second one here as well. I think in the commentary or the prepared remarks you mentioned that you can mitigate tariffs. Just give us any incremental details that you guys, how you see the tariff world right now given the recent IEEPA ruling, what you're kind of baking in the guidance and how you can mitigate those tariffs. Thanks a lot.
這是第一個問題,我也把第二個問題一起問。我想在評論或事先準備的講稿中,你們提到可以緩解關稅影響。能否提供一些額外細節:鑑於近期IEEPA裁定,你們目前如何看待關稅環境、在指引中納入了哪些假設,以及你們如何緩解這些關稅?非常感謝。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
On the medical side, we participate primarily in the alternate care side for delivery -- where delivery of care takes place. Of course, the weather will impact as it often does in the first quarter. We haven't analyzed exactly how the number of procedures will be down this year versus last year, but it's going to be down a little bit. I don't think our customers are really impacted in any material way by any of this legislation or any particular trend going on other than of course people are not being diagnosed, going for diagnosis as much as they did in the COVID period. First of all, COVID's not rampant.
在醫療端,我們主要參與的是替代照護端的交付——也就是照護服務實際發生與提供的地方。當然,天氣一如往常會在第一季造成影響。我們尚未精確分析今年相較去年手術量會下降多少,但會小幅下降。我不認為我們的客戶在任何重大程度上會受到這些立法或任何特定趨勢的影響;除了當然在 COVID 期間,人們不像當時那樣頻繁去做診斷或接受診斷。首先,COVID 並未大規模流行。
And second, if people have colds, they're not worried about it or strep throat or whatever as much as they were during the COVID period. So there's a lot less on the respiratory side. Vaccinations are probably down, although it used to be material for Henry Schein at one point. It's not a material category, but it is a category that our medical people are active in. So I think you can see some challenges on the medical side. I don't think it's going to impact the $13-billion Henry Schein enterprise in any material way. The home care business is doing well. I don't think that's impacted by any legislation or regulation at this particular time.
其次,如果人們感冒了,他們不像在 COVID 期間那樣擔心,或是對鏈球菌性咽喉炎之類的也沒那麼緊張。因此呼吸道相關的需求少了很多。疫苗接種量可能也下降了,雖然在某個時期這對 Henry Schein 來說曾是重要項目。現在它不是重大品類,但仍是一個我們醫療團隊積極參與的品類。所以我認為你可以看到醫療端有一些挑戰。我不認為這會在任何重大程度上影響到年營收 130 億美元的 Henry Schein 企業。居家照護業務表現良好。我不認為在目前這個時間點它會受到任何立法或法規的影響。
So I would say our medical business is quite stable and the decreasing price of gloves is not what it was. It's also stabilized. And we're back to 2019 levels there, maybe a little bit of higher price, but the medical business is relatively stable with as I said, some challenges from the respiratory side. On the tariffs. I think in the prepared remarks we said we anticipate passing on any tariff increases, if there are any, that we need to make to our customers. We have to pay more, but on the other side, we are doing a good job in alternative sourcing.
所以我會說,我們的醫療業務相當穩定,而手套價格的下降幅度也不像之前那樣了。它也已經趨於穩定。我們已回到 2019 年的水準,可能價格略高一些;但如我所說,醫療業務相對穩定,只是在呼吸道相關方面有一些挑戰。關於關稅。我想在事先準備的講稿中我們提到,我們預期若有任何需要轉嫁的關稅上調(如果真的發生),我們會把它轉嫁給客戶。我們必須支付更高成本,但另一方面,我們在替代性採購來源方面做得很好。
So from different countries now I don't know what this flat 15% means, but we should be able to deal with that at least in the short-term. If it's a long-term issue, we'll let you know but I think again within the context of Henry Schein as a $13-billion company, we should be able to deal with this as we've dealt with the tariff generally one part of the business is paying more, another part of the business is mitigating it through other ways, but generally I think we'll be okay.
因此,從不同國家採購——我不確定這個一律 15% 的意思是什麼,但至少在短期內我們應該能夠應對。如果這是長期問題,我們會再告知;但我認為同樣地,在 Henry Schein 作為一家 130 億美元公司的脈絡下,我們應該能夠處理,就像我們過去處理關稅一樣:通常是業務的一部分支付更多成本,另一部分則透過其他方式加以緩解;但整體而言,我認為我們會沒問題。
Okay, so thank you very much. I appreciate everyone calling in the questions.
好的,非常感謝。感謝大家來電提問。
I didn't anticipate doing 121 investor calls but I think the fact that (laughter) Fred is sitting here will be evidence that they will not be -- I will not be doing 122 of these calls. So, thank you for your support. Thank you for your interestHenry Schein as a company, I think, is in a great place. The momentum is good. The strategies are working. Of course in any businesses, there are challenges in one part of the business versus another. This team is well prepared, I think, to deal with the challenges that we know of today and that may even come our way in the future. The team is well organized. The morale, I think, in the company is quite good, and the markets are relatively stable.
我沒想到會做 121 通投資人電話會議,但我想(笑聲)Fred 坐在這裡就足以證明——我不會再做第 122 通了。所以,感謝你們的支持。感謝你們對 Henry Schein 的關注;我認為公司目前處於非常好的位置。動能良好。策略正在奏效。當然,任何企業都會在某些業務面臨挑戰、而其他業務相對順利。我認為這個團隊已做好充分準備,能夠應對我們今天已知的挑戰,以及未來可能出現的挑戰。團隊組織良好。我認為公司士氣相當不錯,市場也相對穩定。
So to conclude today's call, firstly, thank you again for all the support over the years. Thank you to the analysts that are covering the space. I know the space has been a bit rough over the last few years, but I think, it's a good place for investors to invest. The whole healthcare, dental space, and the healthcare, alternate care space are all good areas. And I appreciate those analysts that stuck with the ups and downs and those that have done the detailed work. So thank you very much. So in conclusion, the business is in good shape and maybe Fred will end the call.
因此,作為今天電話會議的結語,首先,再次感謝多年來各位的支持。也感謝覆蓋這個領域的分析師。我知道這個領域過去幾年有些艱難,但我認為對投資人而言,這仍是值得投資的好地方。整個醫療保健、牙科領域,以及醫療保健的替代照護領域,都是很好的方向。我也感謝那些在起起落落中仍持續關注、並做了深入研究的分析師。非常感謝。總之,公司的營運狀況良好,也許 Fred 會來結束這通電話會議。
Thank you.
謝謝。
Fred Lowery - Chief Executive Officer Designate
Fred Lowery - Chief Executive Officer Designate
Stan, thank you very much and I'm looking forward to digging in next week. I've got a 100-day plan that includes a listening tour, so I'm going to get out and meet some Team Schein members, some customers, and suppliers, and of course, I'm looking forward to meeting all of you and spending some time with you and learning -- getting your perspectives on the business.
Stan,非常感謝,我也期待下週深入了解。我有一個 100 天計畫,其中包含一趟傾聽之旅,所以我會出去拜訪並認識一些 Schein 團隊成員、一些客戶與供應商;當然,我也期待與各位見面,花些時間交流並學習——聽取你們對業務的觀點。
And then also I'm going to dig in on the initiatives that are in place and validate the assumptions and I'm looking forward to accelerating and driving more value creation for our shareholders. So thank you very much. Thank you for your interest in Henry Schein and I'm looking forward to working with all of you.
此外,我也會深入檢視目前已在推進的各項倡議,並驗證相關假設;我期待加速推動,為股東創造更多價值。所以非常感謝。感謝你們對 Henry Schein 的關注,我也期待與各位一起合作。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Thank you, Fred.
謝謝你,Fred。
Graham?
Graham?
Graham Stanley - Vice President, Investor Relations and Strategic Financial Project Officer
Graham Stanley - Vice President, Investor Relations and Strategic Financial Project Officer
So next call will be in May.
所以下一次電話會議會在五月。
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Stanley Bergman - Chairman of the Board, Chief Executive Officer
Okay. Thank you, everyone.
好的。謝謝大家。
Operator
Operator
Thank you. This concludes today's teleconference. Please disconnect your lines at this time. Thank you for your participation. Have a wonderful day.
謝謝。今天的電話會議到此結束。請各位此時斷線。感謝各位的參與。祝各位有美好的一天。